Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.43 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891316 | 1.00 | DPP4 (0.46) | DPP4ALDH1A1HTTDPP7FAP | |
| SCHEMBL8612552 | 1.00 | DPP4 (0.46) | DPP4ALDH1A1HTTDPP7FAP | |
| SCHEMBL16935735 | 1.00 | DPP4 (0.46) | DPP4ALDH1A1HTTDPP7FAP | |
| Hydrochloric Acid SCHEMBL3947769 | 0.98 | DPP4 (0.45) | DPP4ALDH1A1HTTDPP7FAP | |
| SCHEMBL1189333 | 0.98 | DPP4 (0.44) | DPP4ALDH1A1HTTDPP7FAP | |
| SCHEMBL2768507 | 0.98 | DPP4 (0.44) | DPP4ALDH1A1HTTDPP7FAP | |
| SCHEMBL389573 | 0.98 | DPP4 (0.44) | DPP4ALDH1A1HTTDPP7FAP | |
| Hydrochloric Acid SCHEMBL4502967 | 0.95 | DPP4 (0.43) | DPP4ALDH1A1HTTDPP7FAP | |
| Hydrochloric Acid SCHEMBL9653875 | 0.95 | DPP4 (0.43) | DPP4ALDH1A1HTTDPP7FAP | |
| SCHEMBL14656016 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522607-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-10919844-B2 | Antibacterials and/or modulators of biofilm formation and methods of using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215704-A1 | ANTIBACTERIALS AND/OR MODULATORS OF BIOFILM FORMATION AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3013805-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES AND THEIR USE AS MNK1 AND/OR MNK2 KINASE INHIBITORS | EVOTEC INT GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-1633349-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20040254374-A1 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | ELI LILLY AND COMPANY | 2004-12-16 | — | — | US | disclosed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1392694-A1 | OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096909-A1 | OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-0696275-B1 | VITAMIN D AMIDE DERIVATIVES | RES INST MEDICINE CHEM (US) | 1998-08-12 | — | — | EP | disclosed |
| US-5756733-A | Vitamin D amide derivatives | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0696275-A1 | VITAMIN D AMIDE DERIVATIVES | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994026707-A1 | VITAMIN D AMIDE DERIVATIVES | HOLMES, MICHAEL, JOHN (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | DPP4 3896/4885ALDH1A1 4221/4885HTT 4008/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | DPP4 82/4885ALDH1A1 4857/4885HTT 914/4885 |
| US-10919844-B2 | Antibacterials and/or modulators of biofilm formation and methods of using the same | NRDC, FIBP, BMP2 | DPP4 1221/4885ALDH1A1 2308/4885HTT 3912/4885 |
| US-20180215704-A1 | ANTIBACTERIALS AND/OR MODULATORS OF BIOFILM FORMATION AND METHODS OF USING THE SAME | NRDC, FIBP, BMP2 | DPP4 1221/4885ALDH1A1 2308/4885HTT 3912/4885 |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | DPP4 1666/4885ALDH1A1 3054/4885HTT 3286/4885 |
| US-20040254374-A1 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | XPNPEP1, XDH, SERPINC1 | DPP4 975/4885ALDH1A1 135/4885HTT 4232/4885 |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, HRH2 | DPP4 3279/4885ALDH1A1 1736/4885HTT 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.